Open access · US-GOV
via ClinicalTrials.gov Clinical trial
An Open-label Uncontrolled Single Centre Investigation for the Evaluation of the Safety and Performance Characteristics of the Dermal Filler mIntense L+AS, Hyaluronic Acid 25 mg/ml (M-INT-LS) for Soft Tissue Augmentation to Correction of Moderate to Deep Wrinkles and Folds
Authors not listed
Mesoestetic Pharma Group S.L. · 2022
Abstract
The investigation is a single-centre, interventional, prospective, non-randomized, open-label, uncontrolled, single-arm, un-blinded investigation for evaluation of the safety and performance of the product mIntense L+AS in the treatment of small skin defects, such as wrinkles or scars. The clinical investigation is interventional and prospective in agreement with the pre-market regulatory status of the product.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-23 MST
Cite this
APA
Anonymous. (2022). An Open-label Uncontrolled Single Centre Investigation for the Evaluation of the Safety and Performance Characteristics of the Dermal Filler mIntense L+AS, Hyaluronic Acid 25 mg/ml (M-INT-LS) for Soft Tissue Augmentation to Correction of Moderate to Deep Wrinkles and Folds. <em>Mesoestetic Pharma Group S.L.</em>. https://clinicaltrials.gov/study/NCT06451822
Vancouver
Anonymous. An Open-label Uncontrolled Single Centre Investigation for the Evaluation of the Safety and Performance Characteristics of the Dermal Filler mIntense L+AS, Hyaluronic Acid 25 mg/ml (M-INT-LS) for Soft Tissue Augmentation to Correction of Moderate to Deep Wrinkles and Folds. Mesoestetic Pharma Group S.L.. 2022.
BibTeX
@misc{anon2022AnOpen,
title = {An Open-label Uncontrolled Single Centre Investigation for the Evaluation of the Safety and Performance Characteristics of the Dermal Filler mIntense L+AS, Hyaluronic Acid 25 mg/ml (M-INT-LS) for Soft Tissue Augmentation to Correction of Moderate to Deep Wrinkles and Folds},
author = {Anonymous},
journal = {Mesoestetic Pharma Group S.L.},
year = {2022},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Mesoestetic Pharma Group S.L. 2022
Open access · US-GOV
An Open-label Uncontrolled Single Centre Investigation for the Evaluation of the Safety and Performance Characteristics of the Dermal Filler mGlobal L+AS, Hyaluronic Acid 20 mg/ml (M-GLO-LS) for Soft Tissue Augmentation to Correction of Light to Moderate Wrinkles and Folds
Mesoestetic Pharma Group S.L. 2022
Open access · US-GOV
An Open-label Uncontrolled Single Centre Investigation for the Evaluation of the Safety and Performance Characteristics of the Dermal Filler, of Hyaluronic Acid 20 mg/ml, (M-AOX-2021) for Soft Tissue Augmentation Intended to be Used as a Temporary Dermal Filler for the Correction of Mild and Moderate Facial Wrinkles.
Innate srl 2023
Open access · US-GOV
A Post-Market, Single-arm, Confirmatory Interventional Clinical Investigation to Evaluate the Performance and Safety of INNEA and INNEA AQUA for the Treatment of Cheek and décolletage Wrinkles
Goldman, Butterwick, Fitzpatrick and Groff 2019
Open access · US-GOV
A Single Center, Prospective, Open-label, Clinical Trial Using Micro-injections of Transparent Hyaluronic Acid Gel (Restylane® Silk) for Rejuvenation of the Aging Cheek
Goldman, Butterwick, Fitzpatrick and Groff 2019
Open access · US-GOV
A Single Center, Prospective, Open-label, Clinical Trial Using Micro-injections of Transparent Hyaluronic Acid Gel (Restylane® Silk) for Rejuvenation of the Aging Cheek
Beijing Friendship Hospital 2016
Open access · US-GOV